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Abstract
Background: A wide variety of high-throughput microarray platforms have been used to identify molecular targets
associated with biological and clinical tumor phenotypes by comparing samples representing distinct pathological
states.
Methods: The gene expression profiles of human cutaneous melanomas were determined by cDNA microarray
analysis. Next, a robust analysis to determine functional classifications and make predictions based on data-oriented
hypotheses was performed. Relevant networks that may be implicated in melanoma progression were also
considered.
Results: In this study we aimed to analyze coordinated gene expression changes to find molecular pathways
involved in melanoma progression. To achieve this goal, ontologically-linked modules with coordinated expression
changes in melanoma samples were identified. With this approach, we detected several gene networks related to
different modules that were induced or repressed during melanoma progression. Among them we observed high
coordinated expression levels of genes involved in a) cell communication (KRT4, VWF and COMP); b) epidermal
development (KLK7, LAMA3 and EVPL); and c) functionally related to kallikreins (EVPL, KLK6, KLK7, KLK8, SERPINB13,
SERPING1 and SLPI). Our data also indicated that hKLK7 protein expression was significantly associated with good
prognosis and survival.
Conclusions: Our findings, derived from a different type of analysis of microarray data, highlight the importance of
analyzing coordinated gene expression to find molecular pathways involved in melanoma progression.
Background
Cutaneous melanoma is considered a complex multigenic
and multifactorial disease that involves both environmental
and genetic factors [1-3]. Its tumorigenesis is often
explained as a progressive transformation of normal mela-
nocytes to nevi that subsequently develop into primary
cutaneous melanomas (PCM) [4,5]. In fact, the develop-
ment of PCM is a classical example of a neoplasm progres-
sion through discrete stages with well-known clinical and
histological features. In spite of its obvious oversimplifica-
tion, this model incorporates the notion that signals trig-
gered by cell-cell and cell-extracellular matrix interactions
are critical for maintaining melanocyte homeostasis [6].
Deregulation of these interactions may disturb the equili-
brium of epidermal melanin units a leading to continuous
proliferation of melanocytes and development of PCM. In
fact, the loss of intercellular adhesion plays a critical role as
a limiting factor during the early steps of melanoma inva-
sion into the dermis, tumor dissemination and metastasis
[7,8]. There are still several gaps in the exact cellular
mechanisms that occur between PCM at early stages (I or
II) and its potential to disseminate as late stage metastatic
melanoma (MM). In an effort to clarify this issue, a wide
variety of high-throughput microarray platforms have been
applied [9,10].
Microarray studies on human skin melanoma produced
a plethora of data without resulting in breakthrough in
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patients [9]. There remains considerable debate in the lit-
erature as to why comparative microarray studies do not
completely coincide with each other [10]. Some reason-
able explanations are that the studies differ in sample
classification (subdivisions), cohort size, type of array and
statistical analysis used. These differences make compari-
sons quite difficult and result in a reduced total cohort
size and diversity, since independent cohorts from differ-
ent studies are hard to be summed [9].
All the studies performed to date analyzed differences
between melanoma cell lines [11,12], between melano-
cytes and PCMs [13], PCMs from different stages and/or
PCMs and metastatic tumors [10,14-19]. In all these
reports, the genes differentially expressed between each
two sample types were identified independently, and in
some studies were classified according to GO groups.
The GOs most frequently altered according to tumor
thickness and/or metastasis were cell proliferation, cell
cycle regulation and mitosis, cell-cell adhesion and cell
extracellular matrix interaction [18]. Interestingly, many
genes up or downregulated in thick compared to thin
PCMs maintained the same profile in metastatic tumors,
indicating that thick primary melanoma tumors may
have the gene expression signature of MM tumors [9,10].
Together, these studies identified several transcriptional
differences that provide insights into the progression of
melanoma and the metastatic process. However, to
delineate the main differences between the molecular sig-
natures of PCM and MM samples, they have focused
only on the differential expression profiles based on mul-
tiple hypothesis testing such as Wilcoxon test [19], Stu-
dent’s t-test [17] or significance analysis of microarrays
(SAM) [9,15,18].
In the present study we adopted a different strategy: we
searched for genes whose expression was coordinately
altered between two conditions: PCMs with different Bre-
slow’s thickness index or PCMs versus metastasis. This
recently described approach looks for changes in the
expression of co-regulated genes that share a common
function. Rather than single-gene analysis, this strategy
might predict whole pathways that are involved in a parti-
cular biological process, named biological module. This
concept was initially described by Segal and collaborators
[20] and was successfully applied by our group to study
esophagus and stomach cancers [21].
Using this approach we identified groups of melano-
mas in which different meaningful ontologically-linked
modules were induced or repressed. We observed
reduced expression of genes involved in cell communi-
cation, epidermal development, skin desquamation and
cell adhesion in MM samples. This loss of cell-stromal
interactions may reflect the gain of migratory potential
of the metastatic cell type. Additionally, we performed
comprehensive pair-wise comparisons among genes
within each module and determined their linear correla-
tion coefficients. We identified linked changes in the
expression of human tissue kallikreins (hKLKs), a family
of serine-proteases that are drawing increased attention
due to their association with various forms of cancer
and other diseases [22-29]. We showed a coordinated
decrease in the expression of hKLKs 6, 7, 8 and 13 (in
terms of mRNA and protein) as the metastatic signature
emerges, suggesting a role of these proteases in the
epithelial-mesenchymal transition of PCM cells. This
also confirmed previous observations that the expression
of hKLK7 is significantly associated with good prognosis
and survival [16,30].
hKLKs are located in a cluster on region q13.3-13.4 of
chromosome 19 [22,28,31-33] and have been implicated
in carcinogenesis due to their role as biomarkers for the
screening, diagnosis, prognosis, and monitoring of var-
ious cancers including prostate, ovarian, breast, testicu-
lar, lung and cervical [22-29]. hKLKs catalyze the
degradation of intercellular cohesive structures (corneo-
desmosomes) at skin surface, being expressed in the
upper spinous and granular layers of the epidermis and
playing a crucial role during keratinocyte cell shedding -
i.e. desquamation [27,32-34].
Many functional aspects of hKLKs need to be better
explored, including their regulation, identification of
specific substrates, their participation in proteolytic cas-
cades, and their clinical applicability as cancer biomar-
kers and therapeutic targets. Our data suggest that the
clinical value of several hKLKs (6, 7, 8 and 13) as bio-
markers for human cutaneous melanoma should be
further evaluated.
Methods
Patients and experimental samples
Tissue samples representing independent PCM and MM
samples were obtained from Hospital A. C. Camargo.
All patients signed an informed consent, and the study
was approved by the internal ethics committee of the
Hospital A. C. Camargo/Ludwig Institute for Cancer
Research. Tissue samples obtained by surgery were
snap-frozen in liquid nitrogen right after removal and
biopsy samples were immediately collected in RNAla-
ter™ (Ambion, Austin, TX). Parallel fragments of the
tissue sections were embebed in paraffin and stained
with hematoxylin/eosin for confirmation of diagnosis.
All samples were analyzed, dissected and re-analyzed by
an expert pathologist (Dr. Gilles Landman). Non-tumor
areas were removed from frozen samples by dissection
and only samples containing at least 70% of tumor cells
within their stroma were selected for RNA extraction. A
detailed description of the 60 samples is presented in
additional file 1.
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Reference sample was obtained by combining five
human cutaneous melanoma cell lines: SK-MEL 05; 17;
28; 37 and 188, kindly provided by Dr. Alan Houghton
(MSKCC, New York, NY, USA). The cells were cultured
in Dulbecco Modified Eagle Medium (Sigma Chemical
Co., St. Louis, MO) supplemented with 10% (v/v) fetal
calf serum, 100 U/mL of penicillin, and 100rg/mL of
streptomycin. Cell culture was maintained in a 37°C
incubator at a moist atmosphere of 5% carbon dioxide.
RNA extraction, amplification, cDNA labeling, and
hybridization
Total RNA from tumor specimens and melanoma cell
lines were isolated with RNeasy
® Midi-columns (Qiagen,
Valencia, CA) following the manufacturer’s instructions.
The quality of total RNA was evaluated by agarose gel
electrophoresis and by measuring absorbance ratios of
260/280 and 260/230. 3.0 μg of total RNA was linearly
amplified using T7-based in vitro transcription following
an optimized protocol [35]. The quality of the amplified
mRNA was evaluated by the same methods employed for
total RNA. Amplified 5’ Poly (U) antisense RNA was con-
verted into cDNA in the presence of aminoallyl-modified
dUTP and coupled to N-hydroxysuccinimidyl esters of
Cy3 and Cy5 (Molecular Probes
®, Invitrogen, Carlsbad,
CA) [36]. Pre-hybridization, hybridization and washing
steps were performed as described previously [21], and
slides were scanned on a laser scanner (ScanArray
Express, Perkin Elmer Life Sciences, Boston, MA). Data
were extracted with ScanArray Express software (Perkin
Elmer Life Sciences, Boston, MA) using the histogram
method. The raw data from hybridizations and experi-
mental conditions are available on the Gene Expression
Omnibus website, accession number GSE17275.
Microarray platform
We employed a customized microarray platform that
contains 4,608 cDNAs representing unique genes with
known full-length sequences that were selected from the
ORESTES [37,38] clone collection derived from the
FAPESP/LICR Human Cancer Genome Project. A map
and gene list for the described microarray platform is
available at Gene Expression Omnibus website, accession
number GPL1930.
Dual-label design
A dual-labeling system was used to generate replicate
data while controlling for possible differences in the effi-
ciency of dye incorporation by different mRNA samples.
Two mRNA samples (experimental and reference) were
separately reverse-transcribed, labeled, mixed, and hybri-
dized in duplicate, with the dye assignments reversed in
the second hybridization. Reference sample was included
in all glass slides to enable the calculation of relative
expression measures for all samples. Since this reference
should not contrast to the experimental samples [39], we
prepared it from a pool of equal amounts of total RNA
from five human cutaneous melanoma cell lines, as cited
above.
Statistical analysis
Data analysis was done using R, an open source inter-
preted computer language for statistical computation and
g r a p h i c s[ 4 0 , 4 1 ]o b t a i n e df r o mt h eC o n t r i b u t e dR
Archive Network http://www.rproject.org, and tools from
the Bioconductor Project http://www.bioconductor.org.
After image acquisition and quantification, spots with
signals lower or equal to background were excluded from
the normalization step. Normalization was performed
using LOWESS, a local non-linear regression fitting
method, using span 0.4 and degree 1 for local-back-
ground subtracted spots [21]. Pearson’s correlation was
used to analyze correlations between experimental and
replicate data.
The survival endpoint was defined as the time interval
from diagnosis until death, and was used as an indicator
of the clinical outcome. Surviving patients and patients
who had died from melanoma were censored at the date
of the last follow-up and at the date of death, respec-
tively. Patients whose death was not related to cancer
were censored at the date of death.
To identify sequences associated with reduced rates of
death from melanoma, we analyzed data for 45 of the 60
patients who had survived for at least 4 years of follow-up.
Four patients who had died from unrelated causes and 11
patients without a reported event but with a follow-up of
less than 4 years were excluded from this analysis. Patients
were then separated into a group of 19 patients who had
survived for 4 or more years, and a group of 26 patients
who had died within 4 years of diagnosis.
Ontologically-linked gene sets
To search for gene expression profiles that were associated
with specific groups of melanomas but not necessarily
related to an individual sample, we applied a module map
similar to that described by Segal et al. [20]. This analysis
evaluated the differential induction or repression of gene
networks representing biological modules. These modules
were defined using a robust analysis to determine func-
tional classifications and make predictions based on data-
oriented hypotheses using mathematical tools, as already
described by our group [42].
We selected biologically meaningful gene sets belong-
ing to the same functional category or pathway related to
biological modules that are important for melanoma pro-
gression such as apoptosis, cell signaling pathways, cell
adhesion, cell communication, cell differentiation, cell
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differentiation, neuronal phenotype, cell shedding, inva-
sion, metastasis and others. After searching the Gene-
Cards
® Human Gene Database [43], Gene Decks
Assorted Gene Sets (GDAGS) and Gene Ontology Hier-
archy [44] for the genes mentioned above, we compiled
4,523, 1,225 and 3,298 genes, respectively. Of those 4,523
genes, 1,306 were represented in our ORESTES platform
and were organized into 123 modules according to the
gene annotation shown in GeneCards
®. Furthermore, 69
tissue or function-specific expressed genes obtained from
the available literature were fitted into the metastasis sig-
nature [11,15,45-47] and functionally hKLK-related genes
[31-33,48,49].
Identification of samples with significant changes in the
status of modules
After data normalization, individual gene expression
values were standardized by subtracting the average
expression calculated over all the samples. This process
adjusted the mean values of each gene to zero and gener-
a t e dad i s c r e t ev e r s i o no ft h ee x p r e s s i o nv a l u e s ,w h e r e
each gene in a sample was defined as 1 (induction) if its
expression was at least 2-fold greater than the average, as
-1 (repression), if its expression value was reduced by at
least 2-fold or as 0 (equal expression).
The number of induced and repressed genes in a mod-
ule of interest was counted for each melanoma sample.
Next, to assess the significance (p-value lower than 0.05)
of the fraction of induced and repressed genes identified
for each sample we applied probabilistic hypotheses tests
following hypergeometric distribution with known para-
meters [20]. After defining the status of a given module
(as induced or repressed) in each melanoma sample, we
counted the number of induced or repressed samples that
comprised a melanoma set discriminated according
to pathological or clinical tumor characteristics: tumor
subtype (PCM and MM samples); melanoma progression
(T1+T2, T3, T4 and MM samples); cancer stage (I, II, III
and IV), metastasis site (LN, CUT and VISC) and clinical
outcome (Surviving and Death). Again using a hypergeo-
metric distribution, we classified each module as signifi-
cantly induced or repressed across the groups of interest
(using p-value lower than 0.05).
Testing consistency of a gene with the status of a module
For any gene (G) belonging to a given module in the
wider gene expression dataset, Segal et al. [20] proposed
a score that described whether the expression of G was
consistent with the overall changes in the expression of
the module. We first identified the subsets of samples in
which G was significantly induced (I) or repressed (R).
Next, we measured the extent to which the expression of
G changed by approximately 2-fold in samples I (or R);
p
i
s and p
r
s denote the fraction of genes in sample (S)t h a t
are induced or repressed, respectively. The score of G is
the sum, over all samples, of weights that depend on the
status of S itself and the status of G in that sample. An
induced S in which G is also induced contributes with
weight -log (p
i
s) ,w h i l ear e p r e s s e dS in which G is also
repressed contributes with weight -log (p
r
s). Conse-
quently, a given G with high score is a gene that behaves
consistently with respect to the status of the module. The
statistical significance of a high score may be easily com-
puted since, under the null hypothesis (genes in each
sample are equally likely to be induced or repressed), the
score is the sum of independent Bernoulli random vari-
ables [20,42].
Discrimination of melanoma samples using SOM
After definition of the genes with higher scores (as
described above), we used a list of 44 non-redundant
genes to discriminate melanomas samples into two main
groups, using Self-Organizing Maps (SOM). Once clus-
ters were obtained, samples were organized hierarchi-
cally based on their correlation distances. Next, we used
Chi-square and Mann-Whitney tests to assess differ-
ences between the SOM groups according to the clinical
and pathological variables of each sample.
Relevance networks
To identify genes with coordinated expression profiles
we made comprehensive pair-wise comparisons of genes
within each module and determined their correlation
coefficients. This is known as a relevance network and
was originally proposed by Butte et al. [50]. This
method computes the squared linear Pearson correlation
coefficientr2
ij between all gene pairs for each melanoma
set (defined in the section “Identifying samples with sig-
nificant changes in the status of modules”), defining a
fully connected graph. Using a re-sampling method, the
algorithm estimates a cut-off value c and splits the
graph into small sub-graphs where r2
ij > c. These sub-
graphs are the relevance networks (RNs).
We adapted this method to identify significant differ-
ences between two RNs, as described previously [51]. The
linear Pearson correlation coefficients of two sample sub-
types r1
ij were computed between every pair of genes. A
Fisher’s Z-transformation [52] was used to translate the
probability distribution of the random variable r1
ij − r2
ij into
an approximated standard normally distributed random
variable, permitting the identification of pairs of genes
with significant (positive or negative) differences between
r1
ij and r2
ij (p-value lower than 0.05).
Based on the p-value of the previous test, we then
constructed a matrix using a green to red heat map
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represents a correlation of +1, and black indicates an
absence of correlation.
Immunohistochemistry staining
To validate the correlation pattern between KLK6 and
KLK7 we used a tissue microarray (TMA) platform con-
taining 162 independent PCM and 28 MM samples ela-
borated by Rezze et al. [30]. hKLK6 (goat anti-kallikrein
6, polyclonal, R&D Systems, Minneapolis, MN) and
hKLK7 (goat anti-kallikrein 7, polyclonal, R&D Systems,
Minneapolis, MN) were used in a standard labeling pro-
tocol. Briefly, sections were deparaffinized in xylene and
rehydrated with graded alcohol and tap water. Antigen
retrieval was done in a heat-controlled pressure cooker
(PASCAL pressure cooker, Dako, Carpinteria, CA) con-
taining 10 mM sodium citrate buffer at pH 6.0 (Dako,
Carpinteria, CA). Endogenous peroxidase activity was
quenched with 3.0% (v/v) hydrogen peroxide (Dako, Car-
pinteria, CA) in methanol for 15 minutes. Protein block
(Dako, Carpinteria, CA) was applied for 20 minutes at
room temperature in a humidified chamber. Primary
antibodies were incubated for two hours at room tem-
perature in a humidified chamber according to pre-estab-
lished dilutions for each antibody. The LSAB
Visualization System (Dako, Carpinteria, CA) and 3,3-
diaminobenzidine chromogen (Dako, Carpinteria, CA)
were used according to the manufacturer’s instructions.
After dehydration, glass slides were coated and mounted
with Entellan mounting medium (Merck KGaA, Darm-
stadt, Germany).
TMA samples were analyzed with the ACIS III (Auto-
mated Cellular Imaging System-ChromaVision Medical
Systems
®, San Juan Capistrano, CA) digital microscopy
system, according to Rezze et al. [30].
Comparative statistical analysis was used to characterize
hKLKs expression according to pathological and clinical
tumor characteristics. Kolmogorov-Smirnov test indicated
that the population did not have a normal distribution.
Hence, Mann-Whitney and Kruskal-Wallis non-para-
metric tests were used to compare median protein expres-
sion values between two and three groups, respectively.
The correlations between hKLKs markers were examined
using Spearman’s coefficient. P-values lower than 0.05
were considered significant.
Results
Evaluation of multiple gene expression profiles by
ontologically-oriented analysis
In order to identify ontologically-linked gene sets with
coordinated expression changes that correlate with mela-
noma progression we analyzed the expression profiles of
60 independent tumors representing PCMs (20) and
MMs (40) (see additional file 1). We used a customized
microarray platform containing 4, 608 ORESTES that has
been successfully used in other studies of our group [53].
All genes represented in the ORESTES microarray
platform were grouped according to biological process
as described by public databases GeneCards
® [43] and
Gene ontology [44]. Furthermore, we grouped tissue or
function-specific genes according to the available
literature.
In the first-pass analysis we identified sample groups
with significant changes in the status of each module.
The categories and the sample groups considered were:
tumor subtype (PCM and MM samples); melanoma pro-
gression (T1+T2, T3, T4 and MM samples); cancer stage
(I, II, III and IV), metastasis site (LN, CUT and VISC)
and clinical outcome (Surviving and Death). By this ana-
lysis we identified 22 significantly non-redundant mod-
ules that were repressed or induced according to the
categories (Table 1).
Next, we evaluated the consistency of the genes that
contributed most significantly (p-values lower than 0.05)
to the changes described in Table 1, as already proposed
by Segal et al. [20] (see additional file 2). As can be
observed, the expression profiles of some genes were
consistently and significantly (cut off set as 10
-5) related
to the status of tumor characteristics. Some examples are
BST2, C1QR1, CCL18, CD53, COL3A1, CTGF, FBN1,
GPR56, LAMA4, LUM and POSTN.
A self-organizing map was then used to group mela-
noma samples into two major clusters on the basis of the
expression profile of 44 non-redundant genes that contrib-
uted most significantly (cut off set as 10
-3.3) to the change
in the status of all modules identified here. As can be
observed in Figure 1, PCM and MM samples could not be
precisely clustered. However, when patient and tumor
characteristics were evaluated, the samples could be sepa-
rated into two distinct main groups with significant asso-
ciation (chi-square test) with tumor subtype (p-value <
0.001) and cancer stage (p-value = 0.003). The right clus-
ter, identified as “less aggressive” in Figure 1, contained
samples from 23 patients, comprising 14 of 20 PCM sam-
ples representing 2 stage I, 7 of 8 stage II, 4 of 19 stage III
and 1 of 31 stage IV patients. The left cluster, identified as
“more aggressive”, contained samples from 37 patients,
comprising 31 of 40 MM samples representing 8 of 19
stage III and 23 of 31 stage IV patients. The PCM (7 of
20) set clustered with most of the MM samples (left clus-
ter) showed a significant increase (p-value = 0.019) in
mean thickness compared to that of the right cluster
(14.51 mm versus 3.84 mm).
Relevance networks in human melanomas
To identify a relevance network (RN) for each subgroup
defined above, a squared linear Pearson correlation coef-
ficient was applied to determine linked expression
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We applied this method for all modules, therefore sev-
eral RNs were found. For further analysis, we considered
only modules (highlighted in Table 1) that were signifi-
cantly changed in at least four different groups in dis-
tinct category types.
Next, the significance of differences between two RNs
was computed for two distinct conditions. Several evalua-
tions had regular |0.4 < r < 0.6 | and moderate |0.6 < r <
0.8 | correlation coefficients with statistical significance (p-
value < 0.005). However, only high correlation coefficients
|0.8 < r < 1.0 | with elevated significance (cut off set as
10
-4.3) were considered (see additional file 3).
For tumor subtype category (PCM and MM), this
approach allowed us to identify a degree of correlation
between the expression levels of genes involved in a)
cell communication (KRT4, VWF and COMP); b) epi-
dermal development (KLK7, LAMA3 and EVPL); and c)
functionally related to kallikreins (EVPL, KLK6, KLK7,
KLK8, SERPINB13, SERPING1 and SLPI).
No relevant networks were found with respect to metas-
tasis site or clinical outcome (data not shown). Only three
networks correlated to cancer stage, two of them in the
module cell communication and one in the set of hKLK
related genes. The network between two genes involved in
cell connecting interactions (GJB1 and DES)s h o w e da
negative and higher correlation (r = -0.943) in stage II
melanoma patients when compared to stage III melanoma
patients (r = 0.54). In contrast, stage II melanoma patients
showed a positive and higher correlation coefficient (r =
0.91) between serpin peptidase inhibitors (SERPINB2 and
SERPINB6) in comparison to stage IV melanoma patients
(r = -0.61) (see additional file 3).
For melanoma progression category (T3, T4 and
MM), only genes ontologically-related to hKLKs (EVPL,
KLK6, KLK7, KLK8, KLK13 and SERPINB13)s h o w e da
positive and high correlation coefficient (mean of 0.971)
in T4 thick melanomas (depth > 4.0 mm), but not in
metastatic tumors (MM). This suggests that the expres-
sion of hKLKs at mRNA level is associated to melanoma
Table 1 The most altered modules based on all comparisons.
MODULES TUMOR
SUBTYPE
MELANOMA
PROGRESSION
CANCER
STAGE
b
METASTASIS
SITE
CLINICAL
OUTCOME
c
PCM MM T1
+T2
a
T3
a T4
a MM I II III IV LN CUT VISC S D
Cell communication (GD) 0.5 -0.4 0.0 0.0 0.0 -0.4 0.0 0.0 0.0 -0.4 0.0 -0.4 0.0 ——
Functionally hKLK-related genes 0.5 -0.2 0.0 0.7 0.0 -0.2 0.0 0.6 0.0 0.0 —— — — —
Epidermal development (GO8544) 0.5 -0.2 0.0 0.0 0.0 -0.2 0.0 0.5 0.0 -0.3 —— — — —
Peptidase activity (GO8233) 0.3 0.0 0.7 0.0 0.0 0.0 ———— — — — — —
Neuroactive ligand receptor (GD) 0.2 0.0 0.0 0.5 0.0 0.0 ———— — — — — —
Metastasis signature 0.0 -0.4 0.0 0.0 0.0 -0.4 0.0 0.0 0.0 -0.5 —— — — —
Cell adhesion (GO7155) 0.0 -0.3 0.0 0.0 0.0 -0.3 ———— — — — — —
Prostaglandin and leukotriene metabolism (GD) —— 0.0 -0.3 0.0 0.0 ———— — — — — —
Intercellular junction (GO5911) —— 0.7 0.0 0.0 0.0 ———— — — — — —
Nervous system development (GO7399) —— 0.7 0.0 0.0 0.0 ———— — — — — —
Negative regulation of progression through cell cycle
(GO45786)
—— — — — — 0.0 0.0 0.0 -0.2 —— — — —
Inflammatory response (GO6954) —— — — — — 0.0 0.0 0.2 0.0 —— — — —
Hydrolase activity (GO16787) —— — — — — 0.0 0.3 0.0 0.0 —— — — —
Extracellular region (GO5576) —— — — — — 0.0 0.0 0.0 -0.5 —— — — —
Extracellular matrix sensu Metazoa (GO5578) —— — — — — 0.0 0.0 0.0 -0.4 —— — — —
Cell motility (GO6928) —— — — — — 0.0 0.0 0.0 -0.2 —— — — —
Alzheimers disease (GD) —— — — — — 0.0 0.0 0.0 0.2 —— — — —
G Protein signaling (GO7187) — — — — — — ————-0.2 0.0 0.0 ——
Leukocyte transendothelial migration — — — — — — ———— 0.2 0.0 0.0 ——
Integral to plasma membrane (GO5887) — — — — — — ———— 0.3 0.0 0.0 ——
Antigen processing and presentation (GD) — — — — — — ———— 0.3 0.0 0.0 ——
Response to stress (GO6950) — — — — — — ———— 0.0 0.0 -0.7 -0.4 0.0
The modules are listed by values representing their status (induced or repressed). Induced modules are depicted by positive values and repressed modules by
negative values.
The modules in italic were selected for showing changes in at least four different groups in distinct category types.
aBreslow’s thickness index according to AJCC staging system.
bCancer stage according to the AJCC staging system.
c Follow up set as more than 4 years: S =
surviving, D = death.
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Page 6 of 15Figure 1 Hierarchical representation of self-organizing maps (SOM) clustered samples based on the expression profiles of biologically
meaningful modules. The clustering of PCM and MM samples was based on similarities in the expression profiles of 44 non-redundant genes
that contributed most significantly (cut off set as 10
-3.3) to the change in the status of all 22 modules identified in this study. The SOM heatmap
shows PCM samples by green bars and MM samples by red bars. Red: higher expression in the tumor than the reference mRNA; green: lower
expression than the reference; black: no change compared to the reference.
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Page 7 of 15progression before the establishment of distant
metastasis.
Kallikreins expression and melanoma progression
This study was the first to report a coordinated decrease
in mRNA expression levels of hKLKs (KLK6, KLK7,
KLK8 and KLK13) as melanoma cells emerges from pri-
mary to metastatic phenotype, suggesting a role of these
proteases in the epithelial-mesenchymal transition of pri-
mary melanoma cells. A recent study from our group
evaluated the protein expression of hKLK6 and hKLK7
by a high-throughput Tissue Microarray Analysis (TMA)
containing 162 independent PCM and 28 MM samples
and showed augmented expression of these two hKLKs
in PCM compared to MM [30]. The present study con-
firms these associations at the transcriptional level and
shows that not only KLK6 and KLK7 but other hKLKs
such as KLK8 and KLK13 are probably coordinately
involved in melanoma progression. We also suggest that
hKLK7 may be used as biomarker for melanoma progres-
sion, since increase in hKLK7 was significantly associated
with good prognosis and survival (see additional file 4).
Interestingly, it has been shown that hKLKs might also
participate in early steps of neoplastic progression by
directly or indirectly promoting or inhibiting cancer-cell
proliferation [28].
Figure 2 shows tissue microarray (TMA) analysis of
hKLK6 and hKLK7 expression in four representative PCM
samples with different Breslow’s thickness index. As can
be observed in the quantitative data shown in Figure 3,
although higher levels of hKLK7 were found in patients
with PCM in comparison to MM samples, the difference
was not significant (p-value = 0.92). A decrease in hKLK7
expression was significantly associated with increase of
Breslow’s thickness index (p-value = 0.006), advanced dis-
ease (p-value = 0.011) and death by melanoma (p-value =
0.008). No association was observed between hKLK6 pro-
tein and tumor subtype or Breslow’s thickness index.
Since we found a gene network correlating KLK6 and
KLK7 mRNA expression (see additional file 3), we applied
the linear Spearman’s correlation coefficient (rho) to
determine the degree of correlation between the expres-
sions of the two genes at protein level measured by TMA.
As can be observed in Figure 4, hKLK7 showed coordi-
nated expression with hKLK6 with a regular Spearman’s
rho correlation coefficient (0.55, p-value < 0.001) in PCM
samples, and moderate Spearman’s rho correlation coeffi-
cient (0.78, p-value < 0.001) in thick PCM samples (depth
> 4.0 mm). These data confirm the reliability of using gene
networks to identify correlated gene expression. In con-
trast to the weak linear Pearson correlation coefficient (r =
0.083) between the expression levels (mRNA) of hKLK6
and hKLK7 in MM samples by our gene networks ana-
lyses, we also found a moderate correlation Spearman’s
rho (0.67, p-value < 0.001) between hKLK6 and hKLK7
protein levels in MM.
To confirm these observations in an independent group
of samples we analyzed 7 PCM samples (additional file 5)
using the same microarray platform, focusing in function-
ally hKLK-related genes network. The data presented in
Figure 5 shows correlated expression not only between
KLK6 and KLK7 but also between other KLK genes, rein-
forcing the association of hKLK module with primary mel-
anoma progression.
Discussion
Several expression studies have been performed in an
attempt to identify genes that could characterize subtypes
of human melanomas, as well as to define verifiable gene
signature profiles with predictive value for metastasis, clin-
ical outcome, or survival [9-19].
Although many differentially expressed genes have been
found, there is still no generally accepted histopathological
or molecular marker defining disease subsets with clini-
cally different outcomes [11,15,16,54,55]. This frustrating
situation reflects the complexity of working with mela-
noma samples and the difficulty of comparing data gener-
ated from different array platforms using distinct statistical
analysis and diverse cohorts [9].
Thin melanomas are the most difficult samples to
obtain in a research setting. For this reason, our thin
PCM sample set is limited to a few samples collected
during this study. Overall, the PCM set comprised mostly
melanomas in the vertical growth phase with average
PCM thicknesses of 3.18 mm and 10.82 mm for inter-
mediate and thick tumors, respectively. Consequently,
the genes identified here may be relevant for the transi-
tion from intermediate to thick tumors (and proceeding
on to metastasis), but they are not especially informative
for earlier steps in tumor progression. The similarity
between the expression profiles of thick PCM and MM
already described in previous studies [10] may explain
why we could not precisely separate PCM from MM in
our clustering SOM analysis (Figure 1).
To date, few studies have performed ontological com-
parisons of genes associated with specific biological pro-
cesses [10,18], and none has analyzed coordinated gene
expression. Here, we have investigated ontologically-linked
gene sets with coordinated expression changes [51] that
correlate with disease progression. We believe that
changes in the relative expression of co-regulated genes
that are ontologically-related may be more useful for pre-
dicting biological pathways in melanoma progression than
the previously performed analysis of changes in single
genes.
With this analytical approach we found a significant
suppression of biological processes related to cell com-
munication, cell adhesion, epidermal development, and
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Page 8 of 15epidermis cell-shedding as melanoma cells emerges from
a primary to a metastatic phenotype (Table 1). This loss
of cell-stroma cross-talk is a well-known behavior of mel-
anoma cells that acquired an increased migratory poten-
tial in an epithelial-mesenchymal transition. These
findings were concordant with a previous ontological
analysis that identified reduced expression or loss of
genes involved in keratinocyte differentiation, epidermal
development, cell adhesion, and cell-cell signaling in
metastatic samples [10,55].
We also observed changes in genes related to cell-to-
cell and cell-to-matrix interactions that may modulate
cross-talk between melanoma cells and the surrounding
stroma: extracellular matrix structural components
(COL3A1, COL4A1, COL17A1, FBN1, FBLN1, FBLN5,
LUM, LAMA3 and LAMA4), adhesive molecules
(ALCAM, C1QR1, CYR61, DSC3, ITGB5, THBS1, THBS3,
THBS4), proteases involved in degradation of the extra-
cellular matrix and possibly tumor cell migration and
proliferation (C 1 R ,D P P 4 ,K L K 6 ,K L K 7 ,K L K 1 3 ,P L A U ),
connective tissue factors (CTGF, VWF) and chemotactic
factors (CCL18, CCL20, CYR61) that mediate cell attach-
ment and tumor cell migration through cell-to-matrix
interactions. Furthermore, we identified changes in
EMP1 and SLPI, which play important roles in cell-cell
adhesion, keratinocyte differentiation and cell shedding.
Figure 2 Immunohistochemistry (tissue microarray - TMA) for hKLK7 and hKLK6 in four representative PCM samples with different
Breslow’s thickness index (T1 to T4). Original magnification 400×.
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s t u d i e sa sb e i n gd o w n - r e g u l ated during melanoma pro-
gression: COL17A1 [15,18], DSC3 [15,18], KLK7 [10,15],
SLPI and KLK8 [18], or over-expressed, e.g. CCL20 [55],
THBS1 [55] and THBS4 [15]. However, other genes were
here described for the first time as differentially
expressed in melanoma tumors, such as COL4A1, FBN1,
LAMA3, LAMA4, C1QR1, CTGF, VWF, CTGF, PLAU,
CYR61, and EMP1.
Based on clustering data, we have identified a decreased
expression of KLK7 in the PCM samples clustered with
most MM samples. This sample set comprised thick mela-
nomas (mean thickness 14.51 mm) that were significantly
associated with poor prognosis (p-value = 0.003). Interest-
ingly, changes in the KLK6 and KLK7 expression profile
were associated with the transition from thin to thick
cutaneous melanomas, being also significantly correlated
to other genes functionally related to keratinocyte differen-
tiation, cell shedding, invasion, and migration (Figure 1).
hKLKs have been implicated in carcinogenesis and often
may serve as biomarkers for the screening, diagnosis,
prognosis, and monitoring of certain prostate, ovarian,
breast, testicular, lung and cervical cancers [22-29].
Accumulating evidences based on their epidermal localiza-
tion and substrate specificity suggest that hKLKs (1, 4, 6, 8,
9, 10, 11, 13 and 14) are desquamation-related enzymes
[33]. hKLK7 has been implicated in keratinocyte cell shed-
ding, catalyzing the degradation of intercellular cohesive
structures (corneodesmosomes) at the skin surface [32,34],
an activity well controlled by specific protease inhibitors
such as SLPI (secretory leukocyte protease inhibitor) [48].
Another important role ascribed to hKLKs is their involve-
ment in extracellular matrix degradation. In this context,
hKLKs 6, 7 and 13 have been implicated in the degrada-
tion of extracellular matrix proteins such as fibronectin,
laminin, vitronectin and collagen [56-59]. Recently, hKLK8
was demonstrated as an active serine protease in human
sweat and non-palmoplantar stratum corneum, also sug-
gesting its involvement in skin desquamation and antimi-
crobial proteolytic cascades [60].
Our findings showed that not only the well studied
hKLK7 but also other members of hKLKs-related genes
were regulated during melanoma progression. In fact, we
observed correlation at protein level between hKLK6 and
7 in PCM samples, and validated this observation by
transcript analysis in an independent dataset.
Figure 3 Comparative statistical analysis of hKLK7 protein levels with respect to clinical and histopatological tumor characteristics.
Non-parametric Mann-Whitney and Kruskal-Wallis tests were used to compare median protein expression values from immunohistochemical
quantitation done using ACIS III digital microscopy system with respect to Tumor subtype (A); Breslow’s thickness index (B); Cancer stage (C) or
Clinical outcome (D). Data derived from TMA assay (Figure 2). P-values lower than 0.05 were considered significant.
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Page 10 of 15Figure 4 Spearman’s rho correlation analysis between expression levels of hKLK6 and hKLK7 in human PCM samples. Scatter-plots
showing a moderate Spearman’s rho correlation coefficient (blue line) between the expression levels of hKLK6 and hKLK7 in PCM (0.3 to 19.5
mm in depth) samples (A), and in thick PCM samples (depth > 4.0 mm) (B).
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platform that does not include all genes that may be
involved in human carcinogenesis, we were able to add
important information to melanoma progression due to
the construction of a cancer related cDNA array and a
careful selection of melanoma related modules.
The strategy of analysis of coordinated gene expression
may help to identify pathways that act in concert to pro-
mote the complex process of melanoma development
and metastasis. The precise mapping of these pathways
may be very important before trying to interfere in tumor
progression, since simultaneous genes should be targeted
by therapy to reach a considerable benefit.
Conclusions
In this study we analyzed coordinated gene expression
changes to find molecular pathways involved in melanoma
progression. We employed a different type of microarray
analysis to evaluate the expression profile of 20 primary
and 40 metastatic human melanomas. We identified onto-
logically-linked modules with coordinated expression
changes in melanoma samples. We then detected several
gene networks related to the different modules that were
induced or repressed during melanoma progression.
Among them we observed high coordinated expression
levels of genes involved in cell communication, epidermal
development and the functionally hKLK-related genes. Our
findings showed that the well studied KLK7 and other
hKLK members (KLK6, 8 and 13) were coordinately
expressed during melanoma progression: These findings
were also validated in an independent dataset. Our data
also indicated that hKLK7 protein expression was signifi-
cantly associated with good prognosis and survival in PCM
samples.
This study, employing a different type of analysis of
microarray data, highlights the importance of analyzing
coordinated gene expression to find molecular pathways
involved in melanoma progression.
Figure 5 Validation of the correlations among hKLK mRNA expression in an independent PCM dataset. Scatter-plots showing Pearson’s
correlation coefficient between the mRNA expression levels of hKLKs in PCM samples. Each graph shows the expression of two kallikreins (the
one in the left and the one below the graph) in all samples. The table shows correlation coefficient and the respective p-value for each kallikrein
pair.
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Page 12 of 15List of abbreviations used in this paper
PCM: Primary cutaneous melanoma; MM: Metastatic
melanoma; CS: Cancer Stage; LN: Lymph node metas-
tases; CUT: Cutaneous metastases; VISC: Visceral
metastases; T: Breslow’s thickness index; S: Surviving; D:
Death; AJCC: American Joint Committee on Cancer;
hKLKs: Human tissue kallikreins.
Additional material
Additional file 1: Description of PCM and MM samples. Samples are
described with respect to tumor histopathological and clinical
characteristics: tumor subtype, Breslow’s thickness index (mm), TNM,
pathologic stage, patient status, follow up.
Additional file 2: Genes that contributed most significantly for the
22 altered modules shown in table 1. List of genes that most
contributed for the non-redundant modules identified in this work. This
file describes gene names, scores and p-values for each module in
distinct melanoma categories: tumor subtype, melanoma progression,
cancer stage, metastasis site and clinical outcome.
Additional file 3: Gene networks with high correlation coefficients
in human melanoma samples. List of the pairs of genes with highest
correlation significance (cut off set as 10
-4.3) in the three most relevant
altered modules: cell communication (GD), epidermal development
(GO8544), functionally hKLK-related. This file describes the correlation
coefficients and the significance (p-values) for each pair in distinct
categories: tumor subtype, cancer stage and melanoma progression.
Additional file 4: Statistical analysis of hKLK6 and 7 protein
expression according to clinical and histopathological parameters.
Immunohistochemistry data analyzed by non-parametric tests (Mann-
Whittney and Kruskal-Wallis) according to clinical outcome, ulceration,
Breslow’s thickness index and cancer stage.
Additional file 5: Description of PCM samples from an independent
microarray dataset. PCM samples are described with respect to tumor
histopathological and clinical characteristics: Breslow’s thickness index
(mm), TNM and pathologic stage.
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